Date: 2015-08-03
Type of information: Licensing agreement
Compound: Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) immunotherapies
Company: Formula Pharmaceuticals (USA - PA) Max Delbrück Center for Molecular Medicine (Germany)
Therapeutic area: Autoimmune diseases - Cancer - Oncology
Type agreement: licensing collaboration
Action mechanism: cell therapy/immunotherapy product.
Disease:
Details: * On August 3, 2015, Formula Pharmaceuticals and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) announced the establishment of an exclusive licensing agreement and strategic collaboration for the development of Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) immunotherapies, using MDC’s proprietary SB100X transposase, a component of the non-viral, Sleeping Beauty transposon-based gene transfer system.The strategic collaboration includes a worldwide exclusive license agreement negotiated by MDC’s technology transfer partner Ascenion, along with collaborative research to be sponsored by Formula. The SB100X system will be incorporated into Formula’s proprietary C.I.K. CAR™ technology platform for the development of therapies targeting significant unmet needs in cancer and autoimmune disease. SB100X is a hyperactive component of the Sleeping Beauty (SB) system that researchers Dr. Zsuzsanna Izsvák and Dr. Zoltán Ivics established while at the University of Minnesota in Minneapolis, USA and which they improved at the MDC.
Financial terms:
Latest news:
